Lee Michael, Bard Frederique, Johnson-Wood Kelly, Lee Celeste, Hu Kang, Griffith Sue G, Black Ronald S, Schenk Dale, Seubert Peter
Elan Pharmaceuticals, Inc., So. San Francisco, CA 94080, USA.
Ann Neurol. 2005 Sep;58(3):430-5. doi: 10.1002/ana.20592.
Serum samples from Alzheimer's disease (AD) patients immunized with Abeta42 (AN1792) were analyzed to determine the induced antibody properties including precise amyloid-beta peptide (Abeta) epitopes and amyloid plaque-binding characteristics. The predominant response in these patients is independent of whether or not meningoencephalitis developed and is against the free amino terminus of Abeta. The immunostaining of amyloid plaques in brain tissue by patient sera is adsorbable by a linear Abeta1-8 peptide, demonstrating that the antibodies are directed predominantly to this epitope and not dependent on Abeta conformations or aggregates specific to plaques. Furthermore, the antibodies are not capable of binding amyloid precursor protein and would be predicted to be competent in facilitating clearance of amyloid plaques in AD brains.
对用β淀粉样蛋白42（AN1792）免疫的阿尔茨海默病（AD）患者的血清样本进行分析，以确定诱导产生的抗体特性，包括精确的淀粉样β肽（Aβ）表位和淀粉样斑块结合特征。这些患者的主要反应与是否发生脑膜脑炎无关，且针对的是Aβ的游离氨基末端。患者血清对脑组织中淀粉样斑块的免疫染色可被线性Aβ1-8肽吸附，这表明抗体主要针对该表位，不依赖于斑块特有的Aβ构象或聚集体。此外，这些抗体不能结合淀粉样前体蛋白，预计能够促进AD大脑中淀粉样斑块的清除。
